Literature DB >> 8145043

Longitudinal analysis of T cell receptor (TCR) gene usage by human immunodeficiency virus 1 envelope-specific cytotoxic T lymphocyte clones reveals a limited TCR repertoire.

S A Kalams1, R P Johnson, A K Trocha, M J Dynan, H S Ngo, R T D'Aquila, J T Kurnick, B D Walker.   

Abstract

Human immunodeficiency virus 1 (HIV-1) infection is associated with a vigorous cellular immune response that allows detection of cytotoxic T lymphocyte (CTL) activity using freshly isolated peripheral blood mononuclear cells (PBMC). Although restricting class I antigens and epitopes recognized by HIV-1-specific CTL have been defined, the effector cells mediating this vigorous response have been characterized less well. Specifically, no studies have addressed the breadth and duration of response to a defined epitope. In the present study, a longitudinal analysis of T cell receptor (TCR) gene usage by CTL clones was performed in a seropositive person using TCR gene sequences as a means of tracking responses to a well-defined epitope in the glycoprotein 41 transmembrane protein. 10 CTL clones specific for this human histocompatibility leukocyte antigen-B14-restricted epitope were isolated at multiple time points over a 31-mo period. All clones were derived from a single asymptomatic HIV-1-infected individual with a vigorous response to this epitope that was detectable using unstimulated PBMC. Polymerase chain reaction amplification using V alpha and V beta family-specific primers was performed on each clone, followed by DNA sequencing of the V-D-J regions. All 10 clones utilized V alpha 14 and V beta 4 genes. Sequence analysis of the TCR revealed the first nine clones isolated to also be identical at the nucleotide level. The TCR-alpha junctional region sequence of the tenth clone was identical to the junctional region sequences of the other nine, but this clone utilized distinct D beta and J beta gene segments. This study provides evidence that the observed high degree of HIV-1-specific CTL activity may be due to monoclonal or oligoclonal expansion of specific effector cells, and that progeny of a particular CTL clone may persist for prolonged periods in vivo in the presence of a chronic productive viral infection. The observed limited TCR diversity against an immunodominant epitope may limit recognition of virus variants with mutations in regions interacting with the TCR, thereby facilitating immune escape.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8145043      PMCID: PMC2191456          DOI: 10.1084/jem.179.4.1261

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  61 in total

1.  Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition.

Authors:  R E Phillips; S Rowland-Jones; D F Nixon; F M Gotch; J P Edwards; A O Ogunlesi; J G Elvin; J A Rothbard; C R Bangham; C R Rizza
Journal:  Nature       Date:  1991-12-12       Impact factor: 49.962

2.  Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus.

Authors:  J W Gnann; J A Nelson; M B Oldstone
Journal:  J Virol       Date:  1987-08       Impact factor: 5.103

3.  In vitro selection of lymphocytic choriomeningitis virus escape mutants by cytotoxic T lymphocytes.

Authors:  T Aebischer; D Moskophidis; U H Rohrer; R M Zinkernagel; H Hengartner
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

4.  Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus.

Authors:  M A Muesing; D H Smith; C D Cabradilla; C V Benton; L A Lasky; D J Capon
Journal:  Nature       Date:  1985 Feb 7-13       Impact factor: 49.962

5.  Organization and sequences of the variable, joining and constant region genes of the human T-cell receptor alpha-chain.

Authors:  Y Yoshikai; S P Clark; S Taylor; U Sohn; B I Wilson; M D Minden; T W Mak
Journal:  Nature       Date:  1985 Aug 29-Sep 4       Impact factor: 49.962

6.  Organization and sequences of the diversity, joining, and constant region genes of the human T-cell receptor beta chain.

Authors:  B Toyonaga; Y Yoshikai; V Vadasz; B Chin; T W Mak
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

7.  HIV-specific cytotoxic T lymphocytes in seropositive individuals.

Authors:  B D Walker; S Chakrabarti; B Moss; T J Paradis; T Flynn; A G Durno; R S Blumberg; J C Kaplan; M S Hirsch; R T Schooley
Journal:  Nature       Date:  1987 Jul 23-29       Impact factor: 49.962

8.  Dominance of one T-cell receptor in the H-2Kb/TNP response.

Authors:  U Hochgeschwender; H G Simon; H U Weltzien; F Bartels; A Becker; J T Epplen
Journal:  Nature       Date:  1987 Mar 19-25       Impact factor: 49.962

9.  CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication.

Authors:  C M Walker; D J Moody; D P Stites; J A Levy
Journal:  Science       Date:  1986-12-19       Impact factor: 47.728

10.  Limiting dilution analysis of cytotoxic T lymphocytes to human immunodeficiency virus gag antigens in infected persons: in vitro quantitation of effector cell populations with p17 and p24 specificities.

Authors:  R A Koup; C A Pikora; K Luzuriaga; D B Brettler; E S Day; G P Mazzara; J L Sullivan
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

View more
  60 in total

1.  Longitudinal phenotypic analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes: correlation with disease progression.

Authors:  G S Ogg; S Kostense; M R Klein; S Jurriaans; D Hamann; A J McMichael; F Miedema
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

Review 2.  Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B.

Authors:  F V Chisari
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

Review 3.  Monitoring of antigen-specific cytolytic T lymphocytes in cancer patients receiving immunotherapy.

Authors:  T L Whiteside
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

4.  Frequency of HLA allele-specific peptide motifs in HIV-1 proteins correlates with the allele's association with relative rates of disease progression after HIV-1 infection.

Authors:  G W Nelson; R Kaslow; D L Mann
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

5.  Large HIV-specific CD8 cytotoxic T-lymphocyte (CTL) clones reduce their overall size but maintain high frequencies of memory CTL following highly active antiretroviral therapy.

Authors:  Michael P Weekes; Mark R Wills; J G Patrick Sissons; Andrew J Carmichael
Journal:  Immunology       Date:  2006-05       Impact factor: 7.397

6.  HLA B*5701-positive long-term nonprogressors/elite controllers are not distinguished from progressors by the clonal composition of HIV-specific CD8+ T cells.

Authors:  Daniel Mendoza; Cassandra Royce; Laura E Ruff; David R Ambrozak; Máire F Quigley; Thurston Dang; Vanessa Venturi; David A Price; Daniel C Douek; Stephen A Migueles; Mark Connors
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

7.  Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus.

Authors:  R P Johnson; R L Glickman; J Q Yang; A Kaur; J T Dion; M J Mulligan; R C Desrosiers
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

8.  CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection.

Authors:  M Matloubian; R J Concepcion; R Ahmed
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

9.  Evaluation of human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T-lymphocyte responses utilizing B-lymphoblastoid cell lines transduced with the CD4 gene and infected with HIV-1.

Authors:  M J McElrath; M Rabin; M Hoffman; S Klucking; J V Garcia; P D Greenberg
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

10.  Persistent high frequency of human immunodeficiency virus-specific cytotoxic T cells in peripheral blood of infected donors.

Authors:  P A Moss; S L Rowland-Jones; P M Frodsham; S McAdam; P Giangrande; A J McMichael; J I Bell
Journal:  Proc Natl Acad Sci U S A       Date:  1995-06-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.